tbuckley/cabot-search huggingface dataset:
Computational Fluid Dynamics (CFD) Analysis of Bioprinting
Authors: Umar Naseef Mohamed Fareez, Syed Ali Arsal Naqvi, Makame Mahmud, Mikail Temirel
Journal: Advanced Healthcare Materials (2024)

Regenerative medicine has evolved with the rise of tissue engineering due to advancements in healthcare and technology. In recent years, bioprinting has been an upcoming approach to traditional tissue engineering practices, through the fabrication of functional tissue by its layer-by-layer deposition process. This overcomes challenges such as irregular cell distribution and limited cell density, and it can potentially address organ shortages, increasing transplant options. Bioprinting fully functional organs is a long stretch but the advancement is rapidly growing due to its precision and compatibility with complex geometries. Computational Fluid Dynamics (CFD), a carestone of computer-aided engineering, has been instrumental in assisting bioprinting research and development by cutting costs and saving time. CFD optimizes bioprinting by testing parameters such as shear stress, diffusivity, and cell viability, reducing repetitive experiments and aiding in material selection and bioprinter nozzle design. This review discusses the current application of CFD in bioprinting and its potential to enhance the technology that can contribute to the evolution of regenerative medicine.
Historical Redlining and Present-Day Nonsuicide Firearm Fatalities
Authors: Ayesha Dholakia, Kendall J. Burdick, Catherine Kreatsoulas, Michael C. Monuteaux, Jennifer Tsai, S.V. Subramanian, Eric W. Fleegler
Journal: Annals of Internal Medicine (2024)

Redlining began in the 1930s with the Home Owners' Loan Corporation (HOLC); this discriminatory practice limited mortgage availability and reinforced concentrated poverty that still exists today. It is important to understand the potential health implications of this federally sanctioned segregation.
Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature
Authors: Annelot J.M. Meijer, Franciscus A. Diepstraten, Marc Ansari, Eric Bouffet, Archie Bleyer, Brice Fresneau, James I. Geller, Alwin D.R. Huitema, Per Kogner, Rudolf Maibach, Allison F. O'Neill, Vassilios Papadakis, Kaukab M. Rajput, Gareth J. Veal, Michael Sullivan, Marry M. van den Heuvel-Eibrink, Penelope R. Brock
Journal: Journal of Clinical Oncology (2024)

Hearing loss occurs in 50%-70% of children treated with cisplatin. Scientific efforts have led to the recent approval of a pediatric formula of intravenous sodium thiosulfate (STS) for otoprotection by the US Food and Drug Administration, the European Medicines Agency, and the Medicines and Health Regulatory Authority in the United Kingdom. To inform stakeholders regarding the clinical utility of STS, the current review summarizes available literature on the efficacy, pharmacokinetics (PK), and safety of systemic STS to minimize cisplatin-induced hearing loss (CIHL).
Corrigendum to “Corrigendum to ‘Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy’ [Journal of Controlled Release 238 (2016) 103–133]” [Journal of Controlled Release (year) Volume 329 (2021) Pages 1283–1285]
Authors: Alexandre Detappe, Sijumon Kunjachan, Lucie Sancey, Vincent Motto-Ros, Douglas Biancur, Pascal Drane, Romain Guieze, G. Mike Makrigiorgos, Olivier Tillement, Robert Langer, Ross Berbeco
Journal: Journal of Controlled Release (2024)
Trends in Age, Sex, and Racial Differences in the Incidence of Infective Endocarditis in Florida and New York
Authors: Anderson Anuforo, Ehimen Aneni, Emmanuel Akintoye, Nnabuchi Anikpezie, Smit D. Patel, Ayorinde Soipe, Eloho Olojakpoke, Devin Burke, Julius Gene Latorre, Priyank Khandelwal, Seemant Chaturvedi, Bruce Ovbiagele, Fadar Oliver Otite
Journal: Circulation (2024)
Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model
Authors: Ágnes Benedict, Gábor Szabó, Kinga Marczell, Bridget Doherty, Silas Martin
Journal: Journal of the National Comprehensive Cancer Network (2024)

Although the FDA Accelerated Approval Program (AAP) has come under scrutiny, the population-level health benefit of the program has not been quantified. Therefore, the objective of this study was to estimate the number of life years gained among patients with cancer that can be attributable to the therapies receiving FDA accelerated approvals in oncology between 2006 and 2022 in the United States.
Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price
Authors: Daniel Tobias Michaeli, Thomas Michaeli
Journal: Journal of the National Comprehensive Cancer Network (2024)

Background: The breakthrough therapy designation (BTD) facilitates the development of drugs with a large preliminary benefit in treating serious or life-threatening diseases. This study analyzes the FDA approval, trials, benefits, unmet needs, and pricing of breakthrough and nonbreakthrough therapy cancer drugs and indications. Patients and Methods: We analyzed 355 cancer indications with FDA approval (2012–2022). Breakthrough and nonbreakthrough indications were compared regarding their FDA approval, innovativeness, clinical trials, epidemiology, and price. Data were extracted from FDA labels, the Global Burden of Disease study, and the Centers for Medicare &amp; Medicaid Services. Hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS), and relative risk (RR) of tumor response were meta-analyzed across randomized controlled trials. Objective response rates (ORRs) were meta-analyzed for single-arm trials. Results: We identified 137 breakthrough and 218 nonbreakthrough cancer indications. The median clinical development time was 3.2 years shorter for breakthrough drugs than for nonbreakthrough drugs (5.6 vs 8.8 years; P =.002). The BTD was more frequently granted to biomarker-directed indications (46% vs 34%; P =.025) supported by smaller trials (median, 149 vs 326 patients; P &lt;.001) of single-arm (53% vs 27%; P &lt;.001) and phase I or II design (61% vs 31%; P &lt;.001). Breakthrough indications offered a greater OS (HR, 0.69 vs 0.74; P =.031) and tumor response (RR, 1.48 vs 1.32; P =.006; ORR, 52% vs 40%; P =.004), but not a PFS benefit (HR, 0.53 vs 0.58; P =.212). Median improvements in OS (4.8 vs 3.2 months; P =.002) and PFS (5.4 vs 3.3 months; P =.005) but not duration of response (8.7 vs 4.7 months; P =.245) were higher for breakthrough than for nonbreakthrough indications. The BTD was more frequently granted to first-in-class drugs (42% vs 28%; P =.001) and first-in-indication treatments (43% vs 29%; P &lt;.001). There were no differences in treatment and epidemiologic characteristics between breakthrough and nonbreakthrough drugs. Breakthrough drugs were more expensive than nonbreakthrough drugs (mean monthly price, $38,971 vs $22,591; P =.0592). Conclusions: The BTD expedites patient access to effective and innovative, but also expensive, new cancer drugs and indications.
Ten Years of Improving Glycemic Control in Pediatric Diabetes Care: Data From the Norwegian Childhood Diabetes Registry
Authors: Heiko Bratke, Eva Biringer, Anastasia Ushakova, Hanna D. Margeirsdottir, Siv Janne Kummernes, Pål R. Njølstad, Torild Skrivarhaug
Journal: Diabetes Care (2024)

To evaluate, from 2013 to 2022, how HbA1c, the incidence of acute complications, and use of diabetes technology changed at the national level in Norway and how glycemic control was associated with use of diabetes technology, carbohydrate counting, or participation in a quality improvement project.
Autonomic Dysfunction Linked to Inhibition of the Na <sub>v</sub> 1.7 Sodium Channel
Authors: Christopher P. Regan, Pierre Morissette, Richard L. Kraus, Erjia Wang, Leticia Arrington, Marissa Vavrek, Jan de Hoon, Marleen Depre, Thomas Lodeweyck, Ignace Demeyer, Tine Laethem, Aubrey Stoch, Arie Struyk
Journal: Circulation (2024)

heart rate control ◼ NAV1.7 voltage-gated sodium channel ◼ pain
Conjugation of IL‐33 to Microporous Annealed Particle Scaffolds Enhances Type 2‐Like Immune Responses In Vitro and In Vivo
Authors: Colleen A. Roosa, Samantha L. Lempke, Riley T. Hannan, Ethan Nicklow, Jeffrey M. Sturek, Sarah E. Ewald, Donald R. Griffin
Journal: Advanced Healthcare Materials (2024)

The inflammatory foreign body response (FBR) is the main driver of biomaterial implant failure. Current strategies to mitigate the onset of a FBR include modification of the implant surface, release of anti-inflammatory drugs, and cell-scale implant porosity. The microporous annealed particle (MAP) scaffold platform is an injectable, porous biomaterial composed of individual microgels, which are annealed in situ to provide a structurally stable scaffold with cell-scale microporosity. MAP scaffold does not induce a discernible foreign body response in vivo and, therefore, can be used a "blank canvas" for biomaterial-mediated immunomodulation. Damage associated molecular patterns (DAMPs), such as IL-33, are potent regulators of type 2 immunity that play an important role in tissue repair. In this manuscript, IL-33 is conjugated to the microgel building-blocks of MAP scaffold to generate a bioactive material (IL33-MAP) capable of stimulating macrophages in vitro via a ST-2 receptor dependent pathway and modulating immune cell recruitment to the implant site in vivo, which indicates an upregulation of a type 2-like immune response and downregulation of a type 1-like immune response.
Rheumatoid arthritis and idiopathic pulmonary fibrosis: a bidirectional Mendelian randomisation study
Authors: Olivia C Leavy, Leticia Kawano-Dourado, Iain D Stewart, Jennifer K Quint, Joshua J Solomon, Raphael Borie, Bruno Crestani, Louise V Wain, Gisli Jenkins, Philippe Dieudé, Cosetta Minelli
Journal: Thorax (2024)

Background A usual interstitial pneumonia (UIP) pattern of lung injury is a key feature of idiopathic pulmonary fibrosis (IPF) and is also observed in up to 40% of individuals with rheumatoid arthritis (RA)-associated interstitial lung disease (RA-ILD). The RA-UIP phenotype could result from either a causal relationship of RA on UIP or vice versa, or from a simple co-occurrence of RA and IPF due to shared demographic, genetic or environmental risk factors. Methods We used two-sample bidirectional Mendelian randomisation (MR) to test the hypothesis of a causal effect of RA on UIP and of UIP on RA, using variants from genome-wide association studies (GWAS) of RA (separately for seropositive (18 019 cases and 991 604 controls) and seronegative (8515 cases and 1 015 471 controls) RA) and of IPF (4125 cases and 20 464 controls) as genetic instruments. Sensitivity analyses were conducted to assess the robustness of the results to violations of the MR assumptions. Findings IPF showed a significant causal effect on seropositive RA, with developing IPF increasing the risk of seropositive RA (OR=1.06, 95% CI: 1.04 to 1.08, p&lt;0.001) which was robust under all models. For the MR in the other direction, seropositive RA showed a significant protective effect on IPF (OR=0.93; 95% CI: 0.87 to 0.99; p=0.032), but the effect was not significant when sensitivity analyses were applied. This was likely because of bias due to exclusion of patients with RA from among the cases in the IPF GWAS, or possibly because our genetic instruments did not fully capture the effect of the complex human leucocyte antigen region, the strongest RA genetic risk factor. Interpretation Our findings support the hypothesis that RA-UIP may be due to a cause–effect relationship between UIP and RA, rather than due to a coincidental occurrence of IPF in patients with RA. The significant causal effect of IPF on seropositive RA suggests that pathomechanisms involved in the development of UIP may promote RA, and this may help inform future guidelines on screening for ILD in patients with RA.
Exhaled Volatile Organic Compounds for Asthma Control Classification in Children with Moderate to Severe Asthma: Results from the SysPharmPediA Study
Authors: Shahriyar Shahbazi Khamas, Yoni Van Dijk, Mahmoud I. Abdel-Aziz, Anne H. Neerincx, Jelle Maarten Blankestijn, Susanne J.H. Vijverberg, Simone Hashimoto, Andrew Bush, Aletta D. Kraneveld, Anna M. Hedman, Antoaneta A. Toncheva, Catarina Almqvist, Christine Wolff, Clare S. Murray, Gunilla Hedlin, Graham Roberts, Ian M. Adcock, Javier Korta-Murua, Klaus Bønnelykke, Louise J. Fleming, Maria Pino-Yanes, Mario Gorenjak, Michael Kabesch, Olaia Sardón-Prado, Paolo Montuschi, Florian Singer, Paula Corcuera Elosegui, Stephen J. Fowler, Susanne Brandstetter, Susanne Harner, Sven-Erik Dahlén, Uroš Potočnik, Urs Frey, Wim van Aalderen, Paul Brinkman, Anke-Hilse Maitland-van der Zee
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Rationale: Early identification of children with poorly controlled asthma is imperative for optimizing treatment strategies. The analysis of exhaled volatile organic compounds (VOCs) is an emerging approach to identify prognostic and diagnostic biomarkers in pediatric asthma. Objectives: To assess the accuracy of gas chromatography-mass spectrometry based exhaled metabolite analysis to differentiate between controlled and uncontrolled pediatric asthma. Methods: This study encompassed a discovery (SysPharmPediA) and validation phase (U-BIOPRED, PANDA). Firstly, exhaled VOCs that discriminated asthma control levels were identified. Subsequently, outcomes were validated in two independent cohorts. Patients were classified as controlled or uncontrolled, based on asthma control test scores and number of severe attacks in the past year. Additionally, potential of VOCs in predicting two or more future severe asthma attacks in SysPharmPediA was evaluated. Measurements and Main Results: Complete data were available for 196 children (SysPharmPediA=100, U-BIOPRED=49, PANDA=47). In SysPharmPediA, after randomly splitting the population into training (n=51) and test sets (n=49), three compounds (acetophenone, ethylbenzene, and styrene) distinguished between uncontrolled and controlled asthmatics. The area under the receiver operating characteristic curve (AUROCC) for training and test sets were respectively: 0.83 (95% CI: 0.65-1.00) and 0.77 (95% CI: 0.58-0.96). Combinations of these VOCs resulted in AUROCCs of 0.74 ±0.06 (UBIOPRED) and 0.68 ±0.05 (PANDA). Attacks prediction tests, resulted in AUROCCs of 0.71 (95% CI 0.51-0.91) and 0.71 (95% CI 0.52-0.90) for training and test sets. Conclusions: Exhaled metabolites analysis might enable asthma control classification in children. This should stimulate further development of exhaled metabolites-based point-of-care tests in asthma.
Mechanical regulation of lipid and sugar absorption by Piezo1 in enterocytes
Authors: Tian Tao, Qing Shu, Yawen Zhao, Wenying Guo, Jinting Wang, Yuhao Shi, Shiqi Jia, Hening Zhai, Hui Chen, Cunchuan Wang, Geyang Xu
Journal: Acta Pharmaceutica Sinica B (2024)

Obesity is primarily caused by excessive intake as well as absorption of sugar and lipid. Postprandial surge in distention pressure and intestinal motility accelerates the absorption of nutrients. The response of intestinal epithelial cells to mechanical stimulation is not fully understood. Piezo1, a mechanosensitive ion channel, is widely expressed throughout the digestive tract. However, its function in intestinal nutrient absorption is not yet clear. In our study, excessive lipid deposition was observed in the duodenum of obese patients, while duodenal Piezo1-CaMKK2-AMPK
Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
Authors: Deidre Wilkins, Yuan Yuan, Yue Chang, Anastasia A. Aksyuk, Beatriz Seoane Núñez, Ulrika Wählby-Hamrén, Tianhui Zhang, Michael E. Abram, Amanda Leach, Tonya Villafana, Mark T. Esser
Journal: Nature Medicine (2024)
Ailanthone ameliorates pulmonary fibrosis by suppressing JUN-dependent MEOX1 activation
Authors: Lixin Zhao, Yuguang Zhu, Hua Tao, Xiying Chen, Feng Yin, Yingyi Zhang, Jianfeng Qin, Yongyin Huang, Bikun Cai, Yonghao Lin, Jiaxiang Wu, Yu Zhang, Lu Liang, Ao Shen, Xi-Yong Yu
Journal: Acta Pharmaceutica Sinica B (2024)

Pulmonary fibrosis poses a significant health threat with very limited therapeutic options available. In this study, we reported the enhanced expression of mesenchymal homobox 1 (MEOX1) in pulmonary fibrosis patients, especially in their fibroblasts and endothelial cells, and confirmed MEOX1 as a central orchestrator in the activation of profibrotic genes. By high-throughput screening, we identified Ailanthone (AIL) from a natural compound library as the first small molecule capable of directly targeting and suppressing MEOX1. AIL demonstrated the ability to inhibit both the activation of fibroblasts and endothelial-to-mesenchymal transition of endothelial cells when challenged by transforming growth factor-β1 (TGF-β1). In an animal model of bleomycin-induced pulmonary fibrosis, AIL effectively mitigated the fibrotic process and restored respiratory functions. Mechanistically, AIL acted as a suppressor of MEOX1 by disrupting the interaction between the transcription factor JUN and the promoter of MEOX1, thereby inhibiting MEOX1 expression and activity. In summary, our findings pinpointed MEOX1 as a cell-specific and clinically translatable target in fibrosis. Moreover, we demonstrated the potent anti-fibrotic effect of AIL in pulmonary fibrosis, specifically through the suppression of JUN-dependent MEOX1 activation.
Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke
Authors: Wenbo Zhao, Sijie Li, Chuanhui Li, Chuanjie Wu, Junmei Wang, Lifei Xing, Yue Wan, Jinhui Qin, Yaoming Xu, Ruixian Wang, Changming Wen, Aihua Wang, Lan Liu, Jing Wang, Haiqing Song, Wuwei Feng, Qingfeng Ma, Xunming Ji, Jianping Ding, Pingping Wang, Yuan Wang, Xiaojun Hao, Bujv Bian, Guanqing Feng, Yujia Xie, Hui Wen, Xinlin Yang, Wenzhao Li, Yuejiang Gui, Jing Hao, Yaqiong Zhang, Qing Zhao, Yang Yang, Rutao Liu, Shanchao Zhang, Zhihui Si, Shan Qiao, Shan Xu, Jing Yuan, Yajuan Shao, Fang Dai, Guofeng Zhang, Yanchao Huo, Wenjing Zhou, Lu Yang, Xufei Cheng, Min Wang, Haidong Hou, Haiying Wang, Hongliang Yan, Yajuan Fu, Bowen Zang, Meiping Zhao, Pingping Wen, Jianying Lv, Xiaojing Lian, Meijuan Kang, Zaihang Zhang, Qing Zhang, Zaiyu Guo, Lianhua Zhao, Xiaoliang Liu, Jing Zheng, Shangsheng Ke, Lin Shao, Xiaoyan Liu, Xiaoming Tao, Yingbing Ke, Hao Liu, Dandan He
Journal: JAMA Neurology (2024)

Evidence supports using antiplatelet therapy in patients with acute ischemic stroke. However, neurological deterioration remains common under the currently recommended antiplatelet regimen, leading to poor clinical outcomes.
Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications
Authors: Anjali A. Dixit, Brian T. Bateman, Mary T. Hawn, Michelle C. Odden, Eric C. Sun
Journal: JAMA (2024)

This cohort study evaluates the risk of postoperative respiratory complications among patients with diabetes undergoing surgery who had vs those who had not a prescription fill for glucagon-like peptide 1 receptor agonists.
Interstitial Lung Disease
Authors: Toby M. Maher
Journal: JAMA (2024)

Interstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation and/or fibrosis of the lung parenchyma associated with progressive dyspnea that frequently results in end-stage respiratory failure. In the US, ILD affects approximately 650 000 people and causes approximately 25 000 to 30 000 deaths per year.
Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders
Authors: Porkizhi Arjunan, Durga Kathirvelu, Gokulnath Mahalingam, Ashish Kumar Goel, Uday George Zacharaiah, Alok Srivastava, Srujan Marepally
Journal: Acta Pharmaceutica Sinica B (2024)

Inherited genetic disorders of the liver pose a significant public health burden. Liver transplantation is often limited by the availability of donor livers and the exorbitant costs of immunosuppressive therapy. To overcome these limitations, nucleic acid therapy provides a hopeful alternative that enables gene repair, gene supplementation, and gene silencing with suitable vectors. Though viral vectors are the most efficient and preferred for gene therapy, pre-existing immunity debilitating immune responses limit their use. As a potential alternative, lipid nanoparticle-mediated vectors are being explored to deliver multiple nucleic acid forms, including pDNA, mRNA, siRNA, and proteins. Herein, we discuss the broader applications of lipid nanoparticles, from protein replacement therapy to restoring the disease mechanism through nucleic acid delivery and gene editing, as well as multiple preclinical and clinical studies as a potential alternative to liver transplantation.
A 24-Year-Old Man With Spastic Ataxia and Hypodontia
Authors: Lissa Marien, Panagiota Tsitsi, Gert Cypers
Journal: JAMA Neurology (2024)

A 24-year-old man presented with progressive gait instability, marked spinal cord atrophy, and dental radiography showing the absence of several elements, microdontia, and taurodontia. What is your diagnosis?
Blood Pressure Management and Falls in Nursing Home Residents—A Matter of Balance
Authors: Muna Thalji Canales, Ronald I. Shorr
Journal: JAMA Internal Medicine (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Opioid Overdose Knowledge Among Adolescents and Young Adults
Authors: Christina E. Freibott, Noel Vest, Michael D. Stein, Sarah Ketchen Lipson
Journal: JAMA Pediatrics (2024)

This cross-sectional study examines awareness of opioid overdose, the ability to administer naloxone, and the willingness to help during an overdose on college campuses across the US.